ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Apollomics Inc

Apollomics Inc (APLM)

0.205
-0.0035
(-1.68%)
Closed July 22 4:00PM
0.1973
-0.0077
( -3.76% )
Pre Market: 8:37AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.1973
Bid
0.1968
Ask
0.1974
Volume
31,292
0.00 Day's Range 0.00
0.1805 52 Week Range 5.80
Market Cap
Previous Close
0.205
Open
-
Last Trade Time
08:35:30
Financial Volume
-
VWAP
-
Average Volume (3m)
1,077,108
Shares Outstanding
89,495,790
Dividend Yield
-
PE Ratio
-0.10
Earnings Per Share (EPS)
-1.93
Revenue
1.22M
Net Profit
-172.6M

About Apollomics Inc

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell... Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Foster City, California, USA
Founded
1970
Apollomics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker APLM. The last closing price for Apollomics was $0.21. Over the last year, Apollomics shares have traded in a share price range of $ 0.1805 to $ 5.80.

Apollomics currently has 89,495,790 shares outstanding. The market capitalization of Apollomics is $18.35 million. Apollomics has a price to earnings ratio (PE ratio) of -0.10.

APLM Latest News

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

FOSTER CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (β€œApollomics” or the β€œCompany”), a late-stage clinical biopharmaceutical company developing multiple...

Apollomics Announces Presentation at the 2024 BIO International Convention

FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (β€œApollomics” or the β€œCompany”) (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug...

Apollomics Announces Private Placement Financing and Addition to Board of Directors

FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address...

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion...

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (β€œApollomics” or the β€œCompany”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (β€œApollomics” or the β€œCompany”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China –...

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (β€œApollomics” or the β€œCompany”), a clinical-stage biopharmaceutical company developing medicines to address...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00432.227979274610.1930.2890.19275931440.22673296CS
4-0.0227-10.31818181820.220.2890.18522968100.22456136CS
12-0.2527-56.15555555560.450.450.180510771080.2404CS
26-0.6927-77.83146067420.890.8990.18055979360.31440279CS
52-5.2727-96.39305301655.475.80.180512184470.75823127CS
156-18.4027-98.939247311818.6490.18059667891.11457953CS
260-18.4027-98.939247311818.6490.18059667891.11457953CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ATPCAgape ATP Corporation
$ 0.389499
(172.38%)
24.66M
WRNTWarrantee Inc
$ 0.7581
(160.52%)
43.43M
GPAKGamer Pakistan Inc
$ 0.3666
(120.71%)
34.16M
NMHINatures Miracle Holding Inc
$ 0.5646
(61.31%)
13.21M
ADILAdial Pharmaceuticals Inc
$ 1.58
(49.06%)
5.92M
JAGXJaguar Health Inc
$ 1.40
(-67.21%)
3M
RNAZTransCode Therapeutics Inc
$ 0.30
(-62.15%)
1.59M
MIRAMIRA Pharmaceuticals Inc
$ 3.66
(-26.95%)
5.81M
BREABrera Holdings PLC
$ 0.5679
(-22.95%)
1.97M
XCURExicure Inc
$ 0.40
(-19.97%)
66.42k
WRNTWarrantee Inc
$ 0.7581
(160.52%)
43.43M
GPAKGamer Pakistan Inc
$ 0.375
(125.77%)
34.19M
ATPCAgape ATP Corporation
$ 0.399
(179.02%)
24.78M
WBUYWeBuy Global Ltd
$ 0.1974
(22.68%)
17.32M
NMHINatures Miracle Holding Inc
$ 0.56
(60.00%)
13.22M

APLM Discussion

View Posts
glenn1919 glenn1919 6 days ago
APLM.............................https://stockcharts.com/h-sc/ui?s=APLM&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 3 weeks ago
APLM 10Q expected July 5
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
APLM new 52 week low
πŸ‘οΈ0
Termite7 Termite7 2 months ago
It'll fall below $0.07ish.....
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
APLM new 52 week low
πŸ‘οΈ0
Frankestin Frankestin 3 months ago
https://ir.apollomicsinc.com/news-releases/news-release-details/apollomics-announces-approval-vebreltinib-china-first-class
Important!
Whoever be short here deserves to know about this disease!
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
APLM new 52 week low
πŸ‘οΈ0
Frankestin Frankestin 5 months ago
So enormous
Short Borrow Fee Rates
2024-02-12 638.05
πŸ‘οΈ0
elks elks 8 months ago
Going to get in.
πŸ‘οΈ0
TommyBoyTrader9460 TommyBoyTrader9460 8 months ago
$APLM
https://x.com/hannahadad8890/status/1729441006372716957?s=61
πŸ‘οΈ0
BoilerRoom BoilerRoom 8 months ago
Will check it out. Thanks
πŸ‘οΈ0
TommyBoyTrader9460 TommyBoyTrader9460 8 months ago
$APLM
https://x.com/hannahadad8890/status/1728985884849299629?s=61
πŸ‘οΈ0
BoilerRoom BoilerRoom 8 months ago
Buy the crypto LCX suppose 700-1000x in 2024. All my opinion of course not financial advice. Disclaimer I purchased $50,000 worth.
πŸ‘οΈ0
BoilerRoom BoilerRoom 8 months ago
Thanks
πŸ‘οΈ0
TommyBoyTrader9460 TommyBoyTrader9460 8 months ago
$APLM
https://x.com/hannahadad8890/status/1728088405362221465?s=61
πŸ‘οΈ0
Jess070283 Jess070283 8 months ago
Huge News!
πŸ‘οΈ0
BoilerRoom BoilerRoom 9 months ago
$APLM in at .85 for swing trade. Out of day trades. Uggggh
πŸ‘οΈ0
TimeFades TimeFades 9 months ago
In 83
πŸ‘οΈ0
TheFinalCD TheFinalCD 9 months ago
FILLED 1.19 FOR A BOUNCE TRADE

BIDS LOWER
πŸ‘οΈ0
TheFinalCD TheFinalCD 9 months ago
sold 1.31 NOW HALTED DOWN 1.21

WONDER WHERE THE BOTTOM IS??
πŸ‘οΈ0
TheFinalCD TheFinalCD 9 months ago
$APLM Overall Risk Low https://dilutiontracker.com/app/search/APLM


THE CONCERNING PART IS 394M OS
https://finviz.com/quote.ashx?t=APLM&ty=c&ta=1&p=d

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172036516&txt2find=APLM
πŸ‘οΈ0
TheFinalCD TheFinalCD 9 months ago
APLM NHOD I FINALLY BOUGHT THE DIP

LIKE A DIP CHIT

1.13 LOWEST FILL
👍️ 1 😂 1 😅 1 🤠 1 🤣 1
TheFinalCD TheFinalCD 9 months ago
1.32 CONGRAT$ TO ANYONE MAKING $
πŸ‘οΈ0
subslover subslover 9 months ago
Everything I learned about mathematics is now meaningless! The only way we make money now is to day trade these PUMPS and it makes no difference that most are horrid POS Companies. Forget the OTC that you and I made most of our money in over the years we have known each other that died 2 years ago
πŸ‘οΈ0
TheFinalCD TheFinalCD 9 months ago
AGREED~! ITS SO BAD IT MAKES IT DIFFICULT TO GAUGE, READ, AND TRADE


ACTUALLY VERY DIFFICULT


APLM @ $1

LONG ?
SHORT ?
OR SIT ON HANDS ?
πŸ‘οΈ0
subslover subslover 9 months ago
Because the entire stock market became corrupt. Sad but true!
👍️ 1
TheFinalCD TheFinalCD 9 months ago
that was yesterdays news, wondering why it was -26% on that news and hit low .52 then 1.17 today>?????

https://finviz.com/quote.ashx?t=APLM&p=d
πŸ‘οΈ0
subslover subslover 9 months ago
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the β€œCompany”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion, at the European Society of Medical Oncology Congress (ESMO) 2023, held in Madrid, Spain from October 20-24, 2023.

The patient with GBM with PTPRZ-MET fusion who had previously received radiotherapy and temozolomide, was reported to have an impressive Partial Response (PR) after 8 weeks of treatment with vebreltinib monotherapy during participation in the SPARTA study (NCT03175224).

β€œPTPRZ-MET fusions are known to cause aggressive forms of GBM and are associated with poor prognosis. We are pleased to achieve positive clinical results in patients with this deadly disease, further demonstrating the potential of vebreltinib as a new treatment for patients with cancers driven by MET alterations,” said Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics. β€œWe are also pleased with the progress in our vebreltinib development programs for treating solid tumors with various MET alterations.” While the company is encouraged by the results, this information may not be indicative of efficacy in a larger GBM patient population.

GBM with MET fusion is an indication pursued by Apollomics and its China partner, Avistone Biotechnology. Avistone sponsors an active-controlled phase 2/3 study of vebreltinib for the treatment of GBM with PTPRZ-MET fusion, and has been in communication with the National Medical Products Administration (NMPA) regarding a supplemental New Drug Application (NDA) for this indication and has recently received priority review from the NMPA.

The ESMO 2023 conference presentation is available on the Apollomics website at https://ir.apollomicsinc.com/news-events/presentations.
πŸ‘οΈ0
Disquisition Disquisition 9 months ago
UNREAL DUMPING
πŸ‘οΈ0
Awl416 Awl416 1 year ago
Volume
πŸ‘οΈ0
Awl416 Awl416 1 year ago
Ridiculous
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 year ago
APLM: CONGRATS, King EZ!!! You are iHub's BEST!!!!
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 year ago
APLM: That iHub crap happens all the time; don't feel alone on THAT score.
πŸ‘οΈ0
makinezmoney makinezmoney 1 year ago
$APLM: I opened this board with SharePrice at $22

And now its up to $43


Looks like the iHUB people are shutting down my board again like previous..... and I'm running out of free posts.

This one started trading today and now its my SECOND time opening up this board. WHAT GIVES ??

https://www.apollomicsinc.com/


GO $APLM
πŸ‘οΈ0